Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: A systematicreview and meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 6, 2015, Pages 8709-8719

  Chen, Wenjie ^a   He, Deshen ^b   Li, Zuyun ^a   Zhang, Xin ^a   Pan, Denghua ^a   Chen, Gang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Glioma; Meta analysis; Prognosis; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ARTICLE; BLOOD ANALYSIS; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PUBLICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW;

EID: 84938386860     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. [1] Zou P, Xu H, Chen P, Yan Q, Zhao L, Zhao P and Gu A. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One 2013; 8: e68782.
2. [2] Huncharek M and Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 2000; 12: 107-112.
3. [3] Levidou G, El-Habr E, Saetta AA, Bamias C, Katsouyanni K, Patsouris E and Korkolopoulou P. P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature. J Neurooncol 2010; 100: 363-371.
4. [4] Chen WJ, He DS, Tang RX, Ren FH and Chen G. Ki-67 is a Valuable Prognostic Factor in Gliomas: Evidence from a Systematic Review and Meta-analysis. Asian Pac J Cancer Prev 2015; 16: 411-420.
5. [5] Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
6. [6] Hicklin DJ and Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
7. [7] Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Yu LK and Song Y. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 2009; 4: 1094-1103.
8. [8] Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL and Perret GY. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006; 94: 1823-1832.
9. [9] Chen J, Tang D, Wang S, Li QG, Zhang JR, Li P, Lu Q, Niu G, Gao J, Ye NY and Wang DR. High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients. Tumour Biol 2014; 35: 2513-2519.
10. [10] Zhang W, Kim R, Quintini C, Hashimoto K, Fujiki M, Diago T, Eghtesad B, Miller C, Fung J, Tan A, Menon KV and Aucejo F. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma under going liver transplantation. Liver Transpl 2015; 21: 101-111.
11. [11] Yu XW, Wu TY, Yi X, Ren WP, Zhou ZB, Sun YQ and Zhang CQ. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol 2014; 35: 155-160.
12. [12] Das S and Marsden PA. Angiogenesis in glioblastoma. N Engl J Med 2013; 369: 1561-1563.
13. [13] Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
14. [14] Higgins JP and Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
15. [15] Lau J, Ioannidis JP and Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
16. [16] Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
17. [17] Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
18. [18] Bian XW, Du LL, Shi JQ, Cheng YS and Liu FX. Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas. Analytical and Quantitative Cytology and Histology 2000; 22: 267-274.
19. [19] Zhong D, Li X and Zhang G. [Multivariate analysis of the parameters related to prognosis of astrocytoma]. Zhonghua Bing Li Xue Za Zhi 2001; 30: 345-349.
20. [20] Hara A and Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol 2004; 108: 43-48.
21. [21] Nam DH, Park K, Suh YL and Kim JH. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 2004; 11: 863-869.
22. [22] Liu XQ, Zhang K, Wang XF and Gao C. The relevance of VEGF, bFGF and PTEN with glioma malignant degree and prognosis. Chinese Journal of Neurosurgery 2004; 20: 14-17.
23. [23] Zhou YH, Hess KR, Liu L, Linskey ME and Yung WK. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol 2005; 7: 485-494.
24. [24] Buccoliero AM, Caldarella A, Gheri CF, Taddei A, Paglierani M, Pepi M, Mennonna P and Taddei GL. Inducible cyclooxygenase (COX-2) in glioblastoma--clinical and immunohistochemical (COX-2-VEGF) correlations. Clin Neuropathol 2006; 25: 59-66.
25. [25] Cheng BC, Wang JH, Feng CG and LI CY. Expressions of osteopontin and vascular endothelial growth factor in brain glioma and their association with the prognosis. Chinese Journal of Neuromedicine 2006; 22-26.
26. [26] Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF and Cloughesy TF. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007; 13: 2592-2598.
27. [27] Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY and Jensen RL. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 2008; 113: 1032-1042.
28. [28] Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ and Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008; 26: 271-278.
29. [29] Yoo H, Sohn S, Nam BH, Min HS, Jung E, Shin SH, Gwak HS and Lee SH. The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis. Int J Mol Med 2010; 26: 3-9.
30. [30] El-Sayed M and Taha MM. Immunohisto-chemical expression of cycloxygenase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival. Turk Neurosurg 2011; 21: 27-35.
31. [31] Piperi C, Samaras V, Levidou G, Kavantzas N, Boviatsis E, Petraki K, Grivas A, Barbatis C, Varsos V, Patsouris E and Korkolopoulou P. Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphometry. Cytokine 2011; 55: 387-395.
32. [32] Saetta AA, Levidou G, El-Habr EA, Panayotidis I, Samaras V, Thymara I, Sakellariou S, Boviatsis E, Patsouris E and Korkolopoulou P. Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome. Virchows Arch 2011; 458: 749-759.
33. [33] Berindan-Neagoe I, Chiorean R, Braicu C, Florian IS, Leucuta D, Crisan D, Cocis A, Balacescu O and Irimie A. Quantitative mRNA expression of genes involved in angiogenesis, coagulation and inflammation in multiforme glioblastoma tumoral tissue versus peritumor al brain tissue: lack of correlation with clinical data. Eur Cytokine Netw 2012; 23: 45-55.
34. [34] Castells X, Acebes JJ, Majos C, Boluda S, Julia-Sape M, Candiota AP, Arino J, Barcelo A and Arus C. Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies. Br J Cancer 2012; 106: 1816-1825.
35. [35] Smith SJ, Tilly H, Ward JH, Macarthur DC, Lowe J, Coyle B and Grundy RG. CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathol 2012; 124: 99-110.
36. [36] Yoo H, Sohn S, Nam BH, Min HS, Jung E, Shin SH, Gwak HS, Lee SH. Expression of CA9 and VEGF in glioma and their relation with prognosis. Int J Mol Med 2012; 916-919.
37. [37] Krauze AV, Won M, Graves C, Corn BW, Muanza TM, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP and Camphausen KA. Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glio-blastoma Multiforme (GBM). Biomark Res 2013; 1: 29.
38. [38] Shin JH, Lee YS, Hong YK and Kang CS. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas. J Neurooncol 2013; 115: 333-341.
39. [39] Xu HW, Huang YJ, Xie ZY, Lin L, Guo YC, Zhuang ZR, Lin XP, Zhou W, Li M, Huang HH, Wei XL, Man K and Zhang GJ. The expression of cytoglobin as a prognostic factor in gliomas: a retrospective analysis of 88 patients. BMC Cancer 2013; 13: 247.
40. [40] Xu Y, Zhong Z, Yuan J, Zhang Z, Wei Q, Song W and Chen H. Collaborative overexpression of matrix metalloproteinase-1 and vascular endothelial growth factor-C predicts adverse prognosis in patients with gliomas. Cancer Epidemiol 2013; 37: 697-702.
41. [41] Cao WD, Kawai N, Miyake K, Zhang X, Fei Z and Tamiya T. Relationship of 14-3-3zeta (zeta), HIF-1alpha, and VEGF expression in human brain gliomas. Brain Tumor Pathol 2014; 31: 1-10.
42. [42] Chiorean R, Berindan-Neagoe I, Braicu C, Florian IS, Leucuta D, Crisan D and Cernea V. Quantitative expression of serum biomarkers involved in angiogenesis and inflammation, in patients with glioblastoma multiforme: Corre-lations with clinical data. Cancer Biomark 2014; 14: 185-194.
43. [43] Clara CA, Marie SK, de Almeida JRW, Wakamatsu A, Oba-Shinjo SM, Uno M, Neville M and Rosemberg S. Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1 alpha in human glioblastoma. Neuropathology 2014; 34: 343-352.
44. [44] Jensen RL, Mumert ML, Gillespie DL, Kinney AY, Schabel MC and Salzman KL. Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro Oncol 2014; 16: 280-291.
45. [45] Nambirajan A, Sharma MC, Gupta RK, Suri V, Singh M and Sarkar C. Study of stem cell marker nestin and its correlation with vascular endothelial growth factor and microvascular density in ependymomas. Neuropathol App Neurobiol 2014; 40: 714-725.
46. [46] Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Carpentier A, Sanson M, Metellus P, Figarella-Branger D, Ouafik L and Chinot O. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol 2014; 16: 392-399.
47. [47] Takano S, Ishikawa E, Nakai K, Matsuda M, Masumoto T, Yamamoto T and Matsumura A. Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial. Onco Targets Ther 2014; 7: 1551-1562.
48. [48] McLendon RE, Lipp E, Satterfield D, Ehinger M, Austin A, Fleming D, Perkinson K, Lefaivre M, Zagzag D, Wiener B, Gururangan S, Fuchs H, Friedman HS, Herndon JE 2nd and Healy P. Prognostic marker analysis in pediatric intracranial ependymomas. J Neurooncol 2015; 122: 255-261.
49. [49] Zeng FY, Tan WY and Hu DS. Expression of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF) in the Treatment of Glioma and Its Significance. China Cancer 2009; 920-923.
50. [50] Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004; 56: 549-580.
51. [51] Peles E, Lidar Z, Simon AJ, Grossman R, Nass D and Ram Z. Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery 2004; 55: 562-567; discussion 567-568.
52. [52] Sampath P, Weaver CE, Sungarian A, Cortez S, Alderson L and Stopa EG. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Control 2004; 11: 174-180.
53. [53] Rijken PF, Bernsen HJ, Peters JP, Hodgkiss RJ, Raleigh JA and van der Kogel AJ. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 2000; 48: 571-582.
54. [54] Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ and Van Meir EG. Hypoxia and the hy poxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005; 7: 134-153.
55. [55] Chan AS, Leung SY, Wong MP, Yuen ST, Cheung N, Fan YW and Chung LP. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998; 22: 816-826.
56. [56] Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP and Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998; 88: 513-520.
57. [57] Korshunov A and Golanov A. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases. J Neurooncol 2000; 48: 13-19.
58. [58] Korshunov A, Golanov A and Timirgaz V. Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol 2002; 58: 255-270.
59. [59] Hlobilkova A, Ehrmann J, Knizetova P, Krejci V, Kalita O and Kolar Z. Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. Neo-plasma 2009; 56: 284-290.
60. [60] Ma C, Li Y, Zhang X, Zhao G and Xu H. Levels of vascular endothelial growth factor and matrix metalloproteinase-9 proteins in patients with glioma. J Int Med Res 2014; 42: 198-204.